adenine has been researched along with B-Cell Lymphoma in 54 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma." | 3.83 | Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. ( Barassi, C; Bernasconi, E; Bertoni, F; Cascione, L; Gaudio, E; Goodstal, S; Kwee, I; Ponzoni, M; Rinaldi, A; Stathis, A; Tarantelli, C; Targa, A; Zucca, E, 2016) |
| " The most common (≥ 20% patients) adverse events were neutropenia, anemia, nasopharyngitis, increased bilirubin, and rash." | 2.82 | Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. ( Aoki, T; Ishizawa, K; Morishita, T; Munakata, W; Ogura, M; Suzuki, T; Takahara, S; Tobinai, K; Uchida, T; Ushijima, Y, 2016) |
| " Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas." | 2.61 | Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019) |
| " In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs." | 2.53 | A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. ( Kim, SS; Lee, CS; Rattu, MA, 2016) |
| " Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo." | 1.42 | Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. ( Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 41 (75.93) | 24.3611 |
| 2020's | 13 (24.07) | 2.80 |
| Authors | Studies |
|---|---|
| Malfona, F | 1 |
| Testi, AM | 1 |
| Moleti, ML | 1 |
| Petrucci, L | 1 |
| Leccisotti, L | 1 |
| Martelli, M | 1 |
| Di Rocco, A | 1 |
| Bories, P | 1 |
| Ysebaert, L | 1 |
| Tahir, F | 1 |
| Sy, J | 1 |
| Reddel, S | 1 |
| Trotman, J | 4 |
| Castillo, JJ | 3 |
| Buske, C | 3 |
| Sarosiek, S | 3 |
| Treon, SP | 4 |
| Nierengarten, MB | 1 |
| Ball, S | 1 |
| Das, A | 1 |
| Vutthikraivit, W | 1 |
| Edwards, PJ | 1 |
| Hardwicke, F | 1 |
| Short, NJ | 1 |
| Borthakur, G | 1 |
| Maiti, A | 1 |
| Jordaens, S | 1 |
| Cooksey, L | 1 |
| Bonney, S | 1 |
| Orchard, L | 1 |
| Coutinho, M | 1 |
| Van Tendeloo, V | 1 |
| Mills, KI | 1 |
| Orchard, K | 1 |
| Guinn, BA | 1 |
| Burke, GAA | 1 |
| Beishuizen, A | 1 |
| Bhojwani, D | 1 |
| Burkhardt, B | 1 |
| Minard-Colin, V | 1 |
| Norris, RE | 1 |
| Kabickova, E | 1 |
| Pinarli, FG | 1 |
| Tacyildiz, N | 1 |
| Howes, A | 1 |
| Jong, J | 1 |
| Liu, G | 1 |
| Nottage, K | 1 |
| Salman, M | 1 |
| Trixhe, XW | 1 |
| Cairo, M | 1 |
| Terao, T | 1 |
| Narita, K | 1 |
| Tsushima, T | 1 |
| Miura, D | 1 |
| Takeuchi, M | 1 |
| Matsue, K | 1 |
| Chong, EA | 1 |
| Roeker, LE | 1 |
| Shadman, M | 1 |
| Davids, MS | 1 |
| Schuster, SJ | 2 |
| Mato, AR | 1 |
| Beauchamp, E | 1 |
| Yap, MC | 1 |
| Iyer, A | 1 |
| Perinpanayagam, MA | 1 |
| Gamma, JM | 1 |
| Vincent, KM | 1 |
| Lakshmanan, M | 1 |
| Raju, A | 1 |
| Tergaonkar, V | 1 |
| Tan, SY | 1 |
| Lim, ST | 1 |
| Dong, WF | 1 |
| Postovit, LM | 1 |
| Read, KD | 1 |
| Gray, DW | 1 |
| Wyatt, PG | 1 |
| Mackey, JR | 1 |
| Berthiaume, LG | 1 |
| Matissek, SJ | 1 |
| Han, W | 1 |
| Karbalivand, M | 1 |
| Sayed, M | 1 |
| Reilly, BM | 1 |
| Mallat, S | 1 |
| Ghazal, SM | 1 |
| Munshi, M | 1 |
| Yang, G | 1 |
| Walker, SR | 1 |
| Elsawa, SF | 1 |
| Liu, M | 1 |
| Deng, H | 1 |
| Mu, J | 1 |
| Li, Q | 1 |
| Pu, Y | 1 |
| Jiang, Y | 1 |
| Deng, Q | 1 |
| Qian, Z | 1 |
| Ping, L | 2 |
| Ding, N | 3 |
| Shi, Y | 2 |
| Feng, L | 2 |
| Li, J | 1 |
| Liu, Y | 2 |
| Lin, Y | 1 |
| Shi, C | 1 |
| Wang, X | 2 |
| Pan, Z | 3 |
| Song, Y | 3 |
| Zhu, J | 2 |
| Barr, PM | 1 |
| Göckeritz, E | 1 |
| Vondey, V | 1 |
| Guastafierro, A | 1 |
| Pizevska, M | 1 |
| Hassenrück, F | 1 |
| Neumann, L | 1 |
| Hallek, M | 2 |
| Krause, G | 1 |
| Thorp, BC | 1 |
| Badoux, X | 1 |
| de Weerdt, I | 1 |
| Koopmans, SM | 1 |
| Kater, AP | 1 |
| van Gelder, M | 1 |
| Shah, B | 1 |
| Zhao, X | 2 |
| Silva, AS | 1 |
| Shain, KH | 1 |
| Tao, J | 1 |
| Brown, JR | 1 |
| Zhang, Z | 1 |
| Zhang, D | 1 |
| Yang, D | 1 |
| Ran, F | 1 |
| Wang, ML | 2 |
| Zhao, G | 1 |
| Sun, Y | 1 |
| Gao, H | 1 |
| Wu, Y | 1 |
| Yang, Y | 1 |
| Zhao, M | 1 |
| Hwang, J | 1 |
| Liu, W | 1 |
| Rao, Y | 1 |
| Beauvais, D | 1 |
| Goossens, JF | 1 |
| Boyle, E | 1 |
| Allal, B | 1 |
| Lafont, T | 1 |
| Chatelut, E | 1 |
| Herbaux, C | 1 |
| Morschhauser, F | 1 |
| Genay, S | 1 |
| Odou, P | 1 |
| Danel, C | 1 |
| Shaikh, H | 1 |
| Khattab, A | 1 |
| Faisal, MS | 1 |
| Chilkulwar, A | 1 |
| Albrethsen, M | 1 |
| Sadashiv, S | 1 |
| Fazal, S | 1 |
| McCarter, SJ | 1 |
| Vijayvargiya, P | 1 |
| Sidana, S | 1 |
| Nault, AM | 1 |
| Lane, CE | 1 |
| Lehman, JS | 1 |
| Wilson, JW | 1 |
| Parikh, SA | 1 |
| Nowakowski, GS | 1 |
| Al-Kali, A | 1 |
| da Cunha-Bang, C | 1 |
| Niemann, CU | 1 |
| Ganatra, S | 1 |
| Sharma, A | 1 |
| Shah, S | 1 |
| Chaudhry, GM | 1 |
| Martin, DT | 1 |
| Neilan, TG | 1 |
| Mahmood, SS | 1 |
| Barac, A | 1 |
| Groarke, JD | 1 |
| Hayek, SS | 1 |
| Dani, S | 1 |
| Venesy, D | 1 |
| Patten, R | 1 |
| Nohria, A | 1 |
| Landsburg, DJ | 1 |
| Hughes, ME | 1 |
| Koike, A | 1 |
| Bond, D | 1 |
| Maddocks, KJ | 1 |
| Guo, L | 1 |
| Winter, AM | 1 |
| Hill, BT | 1 |
| Ondrejka, SL | 1 |
| Hsi, ED | 1 |
| Nasta, SD | 1 |
| Svoboda, J | 1 |
| Bogusz, AM | 1 |
| Tarantelli, C | 2 |
| Zhang, L | 1 |
| Curti, E | 1 |
| Gaudio, E | 2 |
| Spriano, F | 1 |
| Priebe, V | 1 |
| Cascione, L | 2 |
| Arribas, AJ | 1 |
| Zucca, E | 2 |
| Rossi, D | 1 |
| Stathis, A | 2 |
| Bertoni, F | 2 |
| Nguyen, PH | 1 |
| Niesen, E | 1 |
| Geyer, MB | 1 |
| Rivière, I | 1 |
| Sénéchal, B | 1 |
| Wang, Y | 2 |
| Purdon, TJ | 1 |
| Hsu, M | 1 |
| Devlin, SM | 1 |
| Palomba, ML | 1 |
| Halton, E | 1 |
| Bernal, Y | 1 |
| van Leeuwen, DG | 1 |
| Sadelain, M | 1 |
| Park, JH | 1 |
| Brentjens, RJ | 1 |
| Bukhari, A | 1 |
| El Chaer, F | 1 |
| Koka, R | 1 |
| Singh, Z | 1 |
| Hutnick, E | 1 |
| Ruehle, K | 1 |
| Lee, ST | 1 |
| Kocoglu, MH | 1 |
| Shanholtz, C | 1 |
| Badros, A | 1 |
| Hardy, N | 1 |
| Yared, J | 1 |
| Rapoport, AP | 1 |
| Dahiya, S | 1 |
| Aalipour, A | 1 |
| Advani, RH | 2 |
| Akinleye, A | 1 |
| Furqan, M | 1 |
| Adekunle, O | 1 |
| Maddocks, K | 1 |
| Blum, KA | 2 |
| Kohrt, HE | 1 |
| Sagiv-Barfi, I | 1 |
| Rafiq, S | 1 |
| Herman, SE | 1 |
| Butchar, JP | 1 |
| Cheney, C | 1 |
| Zhang, X | 1 |
| Buggy, JJ | 3 |
| Muthusamy, N | 1 |
| Levy, R | 1 |
| Johnson, AJ | 1 |
| Byrd, JC | 1 |
| Sehgal, L | 1 |
| Mathur, R | 1 |
| Braun, FK | 1 |
| Wise, JF | 1 |
| Berkova, Z | 1 |
| Neelapu, S | 1 |
| Kwak, LW | 1 |
| Samaniego, F | 1 |
| Da Roit, F | 1 |
| Engelberts, PJ | 1 |
| Taylor, RP | 1 |
| Breij, EC | 1 |
| Gritti, G | 1 |
| Rambaldi, A | 1 |
| Introna, M | 1 |
| Parren, PW | 1 |
| Beurskens, FJ | 1 |
| Golay, J | 1 |
| Lee, CS | 1 |
| Rattu, MA | 1 |
| Kim, SS | 1 |
| Zhang, LL | 1 |
| Champlin, RE | 1 |
| Alinari, L | 1 |
| Quinion, C | 1 |
| Li, X | 1 |
| Wu, L | 1 |
| Fu, K | 1 |
| Zheng, X | 1 |
| Oh, PS | 1 |
| Hwang, H | 1 |
| Jeong, HS | 1 |
| Kwon, J | 1 |
| Kim, HS | 1 |
| Kim, M | 1 |
| Lim, S | 1 |
| Sohn, MH | 1 |
| Jeong, HJ | 1 |
| Tobinai, K | 1 |
| Ogura, M | 1 |
| Ishizawa, K | 1 |
| Suzuki, T | 1 |
| Munakata, W | 1 |
| Uchida, T | 1 |
| Aoki, T | 1 |
| Morishita, T | 1 |
| Ushijima, Y | 1 |
| Takahara, S | 1 |
| Kwee, I | 1 |
| Barassi, C | 1 |
| Bernasconi, E | 1 |
| Rinaldi, A | 1 |
| Ponzoni, M | 1 |
| Targa, A | 1 |
| Goodstal, S | 1 |
| Roskoski, R | 1 |
| Ruella, M | 1 |
| Kenderian, SS | 1 |
| Shestova, O | 1 |
| Klichinsky, M | 1 |
| Melenhorst, JJ | 1 |
| Wasik, MA | 1 |
| Lacey, SF | 1 |
| June, CH | 1 |
| Gill, S | 1 |
| Kreiniz, N | 1 |
| Bejar, J | 1 |
| Polliack, A | 1 |
| Tadmor, T | 1 |
| Alfaro, J | 1 |
| Pérez de Arce, F | 1 |
| Belmar, S | 1 |
| Fuentealba, G | 1 |
| Avila, P | 1 |
| Ureta, G | 1 |
| Flores, C | 1 |
| Acuña, C | 1 |
| Delgado, L | 1 |
| Gaete, D | 1 |
| Pujala, B | 1 |
| Barde, A | 1 |
| Nayak, AK | 1 |
| Upendra, TVR | 1 |
| Patel, D | 1 |
| Chauhan, S | 1 |
| Sharma, VK | 1 |
| Kanno, S | 1 |
| Almirez, RG | 1 |
| Hung, DT | 1 |
| Chakravarty, S | 1 |
| Rai, R | 1 |
| Bernales, S | 1 |
| Quinn, KP | 1 |
| Pham, SM | 1 |
| McCullagh, E | 1 |
| Honigberg, LA | 1 |
| Smith, AM | 1 |
| Sirisawad, M | 1 |
| Verner, E | 1 |
| Loury, D | 1 |
| Chang, B | 1 |
| Li, S | 1 |
| Thamm, DH | 1 |
| Miller, RA | 1 |
| Ireland, JM | 1 |
| Unanue, ER | 1 |
| Harrison, C | 1 |
| Sharman, JP | 1 |
| Smith, SM | 1 |
| Boyd, TE | 1 |
| Grant, B | 1 |
| Kolibaba, KS | 1 |
| Furman, RR | 1 |
| Rodriguez, S | 1 |
| Chang, BY | 1 |
| Sukbuntherng, J | 1 |
| Izumi, R | 1 |
| Hamdy, A | 1 |
| Hedrick, E | 1 |
| Fowler, NH | 1 |
| Wiestner, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies[NCT04836195] | Phase 1 | 60 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19[NCT00466531] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2007-03-21 | Active, not recruiting | ||
| Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms[NCT01704963] | Phase 1 | 15 participants (Actual) | Interventional | 2012-09-12 | Completed | ||
| Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654] | Phase 1 | 66 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
18 reviews available for adenine and B-Cell Lymphoma
| Article | Year |
|---|---|
[Chimeric antigen receptor T cells].
Topics: Adenine; Antibodies, Bispecific; Antigens, CD19; Antigens, Neoplasm; Cell Engineering; Clinical Tria | 2021 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adenine; Humans; Lymphoma, B-Cell; Piperidines; Randomized Controlled Trials as Topic; Risk | 2020 |
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Clinical Trials as Topic; Disea | 2018 |
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Management; Drug Intera | 2017 |
Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.
Topics: Adenine; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Piperi | 2018 |
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; B | 2018 |
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi | 2019 |
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug | 2018 |
Ibrutinib-Associated Atrial Fibrillation.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrial Fibrillation; Female; Humans; | 2018 |
New roles for B cell receptor associated kinases: when the B cell is not the target.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Humans; Lymphoma, B-Cell; Pipe | 2019 |
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Lymphoma, B-Cell; Molecular Targeted | 2013 |
Ibrutinib and indolent B-cell lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clin | 2014 |
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Human | 2016 |
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans | 2015 |
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans | 2015 |
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Humans; Lymphoma, B-Cell; Piperidines; | 2016 |
3 trials available for adenine and B-Cell Lymphoma
| Article | Year |
|---|---|
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2019 |
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Asian People; Enzy | 2016 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
33 other studies available for adenine and B-Cell Lymphoma
| Article | Year |
|---|---|
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Topics: Adenine; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, B-Cel | 2022 |
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Mult | 2022 |
New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Recurrence | 2023 |
Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
Topics: Adenine; Adult; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Precursor B-Cell L | 2020 |
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
Topics: Adenine; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Immunothera | 2020 |
Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
Topics: Adenine; Adult; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; SOXC Transcription Fac | 2020 |
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benza | 2020 |
Targeting N-myristoylation for therapy of B-cell lymphomas.
Topics: Acyltransferases; Adenine; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tum | 2020 |
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesi | 2021 |
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fem | 2021 |
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chem | 2017 |
Efficacy in the margins of NHL with ibrutinib.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Pyrazole | 2017 |
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Chemokines; Chem | 2017 |
Ibrutinib: coming of age?
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Pyraz | 2018 |
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; H | 2018 |
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Topics: Adenine; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Lymphoma, B-Cell; Piperid | 2018 |
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
Topics: Abscess; Adenine; Antifungal Agents; Aspergillosis; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Orga | 2019 |
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, | 2019 |
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge | 2019 |
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Pro | 2019 |
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Monoclonal, Murine-Derived; Antib | 2014 |
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.
Topics: Adenine; Alternative Splicing; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; DN | 2014 |
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Topics: Adenine; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplasti | 2015 |
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Topics: Acrylamides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis | 2015 |
Blue light emitting diode induces apoptosis in lymphoid cells by stimulating autophagy.
Topics: Adenine; Animals; Apoptosis; Autophagy; B-Lymphocytes; bcl-2-Associated X Protein; Caspase 3; Cell L | 2016 |
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinosito | 2016 |
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
Topics: Adenine; Animals; Antibodies; Antigens, CD19; Cytokines; Heterografts; Humans; Lymphoma, B-Cell; Mic | 2017 |
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines | 2018 |
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell De | 2017 |
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental | 2010 |
Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells.
Topics: Adenine; Animals; Antigen Presentation; Antigen-Presenting Cells; Autophagy-Related Protein 5; B-Lym | 2011 |
Trial watch: BTK inhibitor shows positive results in B cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, B-Cell; Piper | 2012 |
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Prognosis; Prot | 2013 |